2.
Baseline tumor subtype and pathology
| Variable | n (%) | ||||
| All patients
(N=3,020) |
Docetaxel/
anthracycline combo (N=1,421) |
Docetaxel/
anthracycline sequential (N=447) |
Docetaxel/other
(N=705) |
Other
(N=447) |
|
| Tumor phase | |||||
| Stage 0 | 2 (0.1) | 0 (0) | 0 (0) | 2 (0.3) | 0 (0) |
| Stage I | 440 (14.6) | 128 (9.0) | 82 (18.3) | 182 (25.8) | 48 (10.7) |
| Stage IIA | 978 (32.4) | 403 (28.4) | 179 (40.0) | 256 (36.3) | 140 (31.3) |
| Stage IIB | 706 (23.4) | 376 (26.5) | 82 (18.3) | 120 (17.0) | 128 (28.6) |
| Stage IIIA | 604 (20.0) | 350 (24.6) | 64 (14.3) | 98 (13.9) | 92 (20.6) |
| Stage IIIB | 43 (1.4) | 26 (1.8) | 0 (0) | 14 (2.0) | 3 (0.7) |
| Stage IIIC | 223 (7.4) | 127 (8.9) | 36 (8.1) | 29 (4.1) | 31 (6.9) |
| Unknown | 10 (0.3) | 3 (0.2) | 2 (0.4) | 1 (0.1) | 4 (0.9) |
| Data missing | 14 (0.5) | 8 (0.6) | 2 (0.4) | 3 (0.4) | 1 (0.2) |
| Tumor type | |||||
| Ductal carcinoma | 2,554 (84.6) | 1,175 (82.7) | 402 (89.9) | 608 (86.2) | 369 (82.6) |
| Lobular carcinoma | 101 (3.3) | 72 (5.1) | 9 (2.0) | 17 (2.4) | 3 (0.7) |
| Medullary carcinoma | 14 (0.5) | 8 (0.6) | 2 (0.4) | 2 (0.3) | 2 (0.4) |
| Mixed carcinoma | 37 (1.2) | 16 (1.1) | 4 (0.9) | 10 (1.4) | 7 (1.6) |
| Mucinous carcinoma | 12 (0.4) | 6 (0.4) | 3 (0.7) | 2 (0.3) | 1 (0.2) |
| Tubular carcinoma | 11 (0.4) | 3 (0.2) | 1 (0.2) | 6 (0.9) | 1 (0.2) |
| Other | 141 (4.7) | 72 (5.1) | 16 (3.6) | 28 (4.0) | 25 (5.6) |
| Unknown | 146 (4.8) | 69 (4.9) | 9 (2.0) | 29 (4.1) | 39 (8.7) |
| Data missing | 4 (0.1) | 0 (0) | 1 (0.2) | 3 (0.4) | 0 (0) |
| Tumor size (cm) | |||||
| <2 | 317 (28.6) | 94 (22.5) | 115 (28.4) | 90 (39.8) | 18 (30.5) |
| ≥2 | 759 (68.6) | 319 (76.5) | 273 (67.4) | 126 (55.8) | 41 (69.5) |
| Data missing | 31 (2.8) | 4 (1.0) | 17 (4.2) | 10 (4.4) | 0 (0) |
| NA* | 1,913 | 1,004 | 42 | 479 | 388 |
| Lymphovascular invasion | |||||
| Yes | 140 (12.6) | 50 (12.0) | 55 (13.6) | 24 (10.6) | 11 (18.6) |
| No | 577 (52.1) | 224 (53.7) | 205 (50.6) | 118 (52.2) | 30 (50.8) |
| Unknown | 390 (35.2) | 143 (34.3) | 145 (35.8) | 84 (37.2) | 18 (30.5) |
| NA* | 1,913 | 1,004 | 42 | 479 | 388 |
| Estrogen receptor | |||||
| Negative | 1,088 (36.0) | 487 (34.3) | 184 (41.2) | 234 (33.2) | 183 (40.9) |
| Positive | 1,868 (61.9) | 891 (62.7) | 258 (57.7) | 465 (66.0) | 254 (56.8) |
| Unknown | 61 (2.0) | 42 (3.0) | 5 (1.1) | 4 (0.6) | 10 (2.2) |
| Data missing | 3 (0.1) | 1 (0.1) | 0 (0) | 2 (0.3) | 0 (0) |
| Progesterone receptor | |||||
| Negative | 1,297 (42.9) | 595 (41.9) | 212 (47.4) | 281 (39.9) | 209 (46.8) |
| Positive | 1,654 (54.8) | 781 (55.0) | 230 (51.5) | 416 (59.0) | 227 (50.8) |
| Table 2 (continued) | |||||